Ratings Moves: IMOS...
Health Care: Drugs
Synageva BioPharma Corp (GEVA: NASDAQ)
$38.79 -1.08 | -2.71%
05/20/13 - 04:00 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | 71,900 | 71,900 | 0 | 0 | 0 | 0 | 0 |
| Shares Bought | 80,000 | 89,852 | 9,852 | 9,852 | 0 | 0 | 0 |
| Shares Sold | 8,100 | 17,952 | 9,852 | 9,852 | 0 | 0 | 0 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 28.11M | 27.74M | 27.67M | 27.74M | 23.42M | 23.26M | 23.29M |
| Shares Bought | 4.85M | 4.26M | 4.17M | 4.70M | 4.64M | 5.13M | 5.35M |
| Shares Sold | 1.07M | 962,576 | 1.01M | 3.49M | 3.61M | 3.59M | 3.53M |
Portfolios with GEVA
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks At New 52-Week Highs...
Latest GEVA Headlines from TheStreet
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) 05.10.13 | 12:05 pm
- GEVA Crosses Below Key Moving Average Level 05.01.13 | 11:05 am
- Top Insider Trades: AEGR GEVA DRI HNSN 01.16.13 | 09:01 am
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: NCR PLCE GEVA LEI 01.09.13 | 09:01 am
- 5 Stocks Insiders Love Right Now 07.18.12 | 10:07 am
- Insiders Trading GEVA, GNOM, VPRT, HSON 07.16.12 | 09:07 am
- Insiders Trading DNKN, GEVA, HMPR, PGCG 06.29.12 | 09:06 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- 8 Stocks Rising on Monster Volume 02.29.12 | 03:02 pm
Press Releases for GEVA
- Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology - Business Wire 03.26.13 | 07:03 am
- Synageva BioPharma™ Reports 2012 Full Year Financial Results - Business Wire 03.11.13 | 04:03 pm
- Synageva BioPharma™ To Host 2012 Fourth Quarter And Full Year Financial Results Conference Call On March 11 - Business Wire 03.01.13 | 12:03 pm
- Synageva BioPharma™ Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2013 - Business Wire 02.28.13 | 06:02 am
- Synageva BioPharma™ To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 11:02 am
- Synageva BioPharma™ Initiates Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency - Business Wire 02.11.13 | 07:02 am
- Synageva BioPharma™ To Present At The Leerink Swann Global Healthcare Conference 2013 - Business Wire 02.06.13 | 04:02 pm
- Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase Alfa In Adults With Late Onset LAL Deficiency - Business Wire 02.04.13 | 04:02 pm
- Synageva BioPharma™ Highlights Data Presentations At The 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium - Business Wire 01.30.13 | 04:01 pm
- Synageva BioPharma Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares - Business Wire 01.09.13 | 09:01 am
Partner Headlines for GEVA
- UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment - Benzinga 03.12.13 | 09:03 am
- UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp. - Benzinga 11.07.12 | 08:11 am
- Winning Trades Based on Analyst Ratings for June 25 - Benzinga 06.25.12 | 01:06 pm
- UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, $76 PT - Benzinga 04.20.12 | 09:04 am
